Non-motor symptoms in Parkinson’s disease

被引:14
作者
Ariane Park
Mark Stacy
机构
[1] The Ohio State University,Department of Neurology
[2] Duke University Medical Center,Division of Neurology
来源
Journal of Neurology | 2009年 / 256卷
关键词
Parkinson’s disease; Non-motor symptoms; Dopaminergic treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease is a hypokinetic movement disorder with cardinal motor features of bradykinesia, resting tremor and rigidity. However, non-motor symptoms, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances are gaining increasing attention. These non-motor symptoms may be intrinsic to the disease pathology or may be results of treatment with dopaminergic agents. Given that most, if not all, patients with Parkinson’s disease will experience non-motor symptoms, it is important to be sensitive to these phenomena, especially since some non-motor signs may precede motor impairment. Treatment may include interventions independent of traditional, dopaminergic anti-Parkinson therapy or may be tailored to increase or reduce dopamine responsiveness of the symptom.
引用
收藏
页码:293 / 298
页数:5
相关论文
共 299 条
[1]  
Aarsland D(2001)Risk of dementia in Parkinson’s disease: a community-based, prospective study Neurology 56 730-736
[2]  
Andersen K(2002)Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study J Neurol Neurosurg Psychiatry 72 708-712
[3]  
Larsen JP(2003)Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease Mov Disord 18 287-293
[4]  
Lolk A(2007)Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease Sleep Med 8 60-64
[5]  
Nielsen H(2003)Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study Arch Neurol 60 1745-1748
[6]  
Kragh-Sorensen P(2003)Staging of brain pathology related to sporadic Parkinson’s disease Neurobiol Aging 24 197-211
[7]  
Aarsland D(2007)Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study Mov Disord 22 2037-2042
[8]  
Laake K(2002)Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease Biol Psychiatry 52 438-445
[9]  
Larsen JP(2005)Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg Curr Med Res Opin 21 71-80
[10]  
Janvin C(2007)Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease Neurology 68 1455-1459